The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Drug induced liver injury and its relationship to autoimmune hepatitis
Abstract
Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitisJournal of HepatologyVol. 55Issue 4PreviewMultiple instances of DILI in the same patient with drugs of similar structure or function as well as completely unrelated drugs are not well understood and poorly documented. We have sought evidence of the frequency and characteristics of patients who have experienced two DILI episodes due to different drugs. Full-Text PDF Drug-induced liver injury (DILI) is a leading cause of acute liver failure [[1]Chalasani N. Fontana R.J. Bonkovsky H.L. Watkins P.B. Davern T. Serrano J. et al.Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.Gastroenterology. 2008; 135 (e1921–1924): 1924-1934Abstract Full Text Full Text PDF PubMed Scopus (661) Google Scholar] and is of major importance to the pharmaceutical industry, as it is the most frequent reason for withdrawal of substances from the market. More than 1000 different drugs and herbal remedies have been described to cause DILI. Some drugs cause a dose-dependent toxicity which can be anticipated – a well known example is acetaminophen. The vast majority of DILI cases cannot be foreseen and are, therefore, termed idiosyncratic. Oxidative stress, reactive metabolites, mitochondrial toxicity, modulation of drug metabolizing transporters, induction of apoptosis or necrosis, as well as immunoall…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The term "immune-mediated DILI" is associated with many drugs that are not associated with well recognised autoimmune features.
“The term “immune-mediated DILI” is also associated with many drugs that are not associated with well recognised autoimmune features.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [19]
The liver damage in DI-ALH usually manifests clinically within 3 months of drug exposure, but can appear after more prolonged latency.
“The liver damage in DI-ALH usually manifests clinically within 3 months of drug exposure, but can appear after more prolonged latency.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [19]
The presence of autoantibodies in DI-ALH is usually related to specific drug types such as methyldopa, hydralazine, minocycline, nitrofurantoin, statins and infliximab.
“The presence of autoantibodies in DI-ALH is usually related to specific drug types such as methyldopa, hydralazine, minocycline, nitrofurantoin, statins and infliximab.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [19]
Citations
Cites
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Flagged first, then by citations
Research works printed but not linked: 18
- Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 · DOI · Paper page
- El-Serag, 2002, Diabetes increases the risk of acute hepatic failure, Gastroenterology, 122, 1822, 10.1053/gast.2002.33650 · DOI
- Bjornsson, 2009, The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice, J Hepatol, 50, 511, 10.1016/j.jhep.2008.10.021 · DOI · Paper page
- Bjornsson, 2010, Review article: drug-induced liver injury in clinical practice, Aliment Pharmacol Ther, 32, 3, 10.1111/j.1365-2036.2010.04320.x · DOI · Paper page
- Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI
- Boelsterli, 2007, Mitochondrial abnormalities – a link to idiosyncratic drug hepatotoxicity?, Toxicol Appl Pharmacol, 220, 92, 10.1016/j.taap.2006.12.013 · DOI
- Lucena, 2008, Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury, Hepatology, 48, 588, 10.1002/hep.22370 · DOI
- Hunt, 2010, Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review, Hepatology, 52, 2216, 10.1002/hep.24022 · DOI
- Sharma, 2010, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity, Clin Infect Dis, 50, 833, 10.1086/650576 · DOI
- Lucena, 2011, Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish registry, The dilemma of the relationship to autoimmune hepatitis. J Hepatol, 55, 70
- Alvarez, 1999, International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis, J Hepatol, 31, 929, 10.1016/S0168-8278(99)80297-9 · DOI · Paper page
- Hennes, 2008, Simplified criteria for the diagnosis of autoimmune hepatitis, Hepatology, 48, 169, 10.1002/hep.22322 · DOI · Paper page
- Manns, 2010, Diagnosis and management of autoimmune hepatitis, Hepatology, 51, 2193, 10.1002/hep.23584 · DOI · Paper page
- Bjornsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
- Bernal, 2007, The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study, J Hepatol, 47, 664, 10.1016/j.jhep.2007.05.011 · DOI
- Efe, 2010, Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agents, Hepatology, 52, 2246, 10.1002/hep.23834 · DOI
- von Kalckreuth, 2008, Unmasking autoimmune Hepatitis under immunomodulatory treatment of multiple sclerosis – not only beta interferon, Am J Gastroenterol, 103, 2147, 10.1111/j.1572-0241.2008.01982_9.x · DOI
- Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J Hepatol, 53, 1049, 10.1016/j.jhep.2010.05.033 · DOI
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationIntrahepatic cholestasis in common chronic liver diseases
Jüngst, C., Berg, T., Cheng, J., Green, R. M., Jia, J., Mason, A. L., & Lammert, F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12128 · Cited by 82
Metadata
- Authors
- Weiler-Normann, C., & Schramm, C.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 55
- Issue
- 4
- Pages
- 747-749
- ISSN
- 0168-8278
- Cited by
- 92
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
